Atropine for the Prevention of Myopia Progression in Children

A Report by the American Academy of Ophthalmology


      To review the published literature on the efficacy of topical atropine for the prevention of myopic progression in children.


      Literature searches were last conducted in December 2016 in the PubMed database with no date restrictions, but were limited to studies published in English, and in the Cochrane Library database without any restrictions. The combined searches yielded 98 citations, 23 of which were reviewed in full text. Of these, 17 articles were deemed appropriate for inclusion in this assessment and subsequently were assigned a level of evidence rating by the panel methodologist.


      Seventeen level I, II, and III studies were identified. Most of the studies reported less myopic progression in children treated with atropine compared with various control groups. All 8 of the level I and II studies that evaluated primarily myopic progression revealed less myopic progression with atropine (myopic progression ranging from 0.04±0.63 to 0.47±0.91 diopters (D)/year) compared with control participants (myopic progression ranging from 0.38±0.39 to 1.19±2.48 D/year). In studies that evaluated myopic progression after cessation of treatment, a rebound effect was noted. Several studies evaluated the optimal dosage of atropine with regard to myopic progression, rebound after treatment cessation, and minimization of side effects. Lower dosages of atropine (0.5%, 0.1%, and 0.01%) were found to be slightly less effective during treatment periods of 1 to 2 years, but they were associated with less rebound myopic progression (for atropine 0.01%, mean myopic progression after treatment cessation of 0.28±0.33 D/year, compared with atropine 0.5%, 0.87±0.52 D/year), fewer side effects, and similar long-term results for myopic progression after the study period and rebound effect were considered. The most robust and well-designed studies were carried out in Asian populations. Studies involving patients of other ethnic backgrounds failed to provide sufficient evidence of an effect of atropine on myopic progression.


      Level I evidence supports the use of atropine to prevent myopic progression. Although there are reports of myopic rebound after treatment is discontinued, this seems to be minimized by using low doses (especially atropine 0.01%).

      Abbreviations and Acronyms:

      ATOM (Atropine for the Treatment of Myopia), D (diopter)
      To read this article in full you will need to make a payment
      Subscribe to Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Pan C.W.
        • Klein B.E.
        • Cotch M.F.
        • et al.
        Racial variations in the prevalence of refractive errors in the United States: the multi-ethnic study of atherosclerosis.
        Am J Ophthalmol. 2013; 155: 1129-1138
        • Kempen J.H.
        • Mitchell P.
        • Lee K.E.
        • et al.
        The prevalence of refractive errors among adults in the United States, Western Europe, and Australia.
        Arch Ophthalmol. 2004; 122: 495-505
        • Vitale S.
        • Sperduto R.D.
        • Ferris 3rd, F.L.
        Increased prevalence of myopia in the United States between 1971–1972 and 1999–2004.
        Arch Ophthalmol. 2009; 127: 1632-1639
        • Fan D.S.
        • Lam D.S.
        • Lam R.F.
        • et al.
        Prevalence, incidence, and progression of myopia of school children in Hong Kong.
        Invest Ophthalmol Vis Sci. 2004; 45: 1071-1075
        • Wong T.Y.
        • Foster P.J.
        • Hee J.
        • et al.
        Prevalence and risk factors for refractive errors in adult Chinese in Singapore.
        Invest Ophthalmol Vis Sci. 2000; 41: 2486-2494
        • Lin L.L.
        • Shih Y.F.
        • Hsiao C.K.
        • Chen C.J.
        Prevalence of myopia in Taiwanese schoolchildren: 1983 to 2000.
        Ann Acad Med Singapore. 2004; 33: 27-33
        • Tay M.T.
        • Au Eong K.G.
        • Ng C.Y.
        • Lim M.K.
        Myopia and educational attainment in 421,116 young Singaporean males.
        Ann Acad Med Singapore. 1992; 21: 785-791
        • Ip J.M.
        • Saw S.M.
        • Rose K.A.
        • et al.
        Role of near work in myopia: findings in a sample of Australian school children.
        Invest Ophthalmol Vis Sci. 2008; 49: 2903-2910
        • Rose K.A.
        • Morgan I.G.
        • Ip J.
        • et al.
        Outdoor activity reduces the prevalence of myopia in children.
        Ophthalmology. 2008; 115: 1279-1285
        • Marcus M.W.
        • de Vries M.M.
        • Junoy Montolio F.G.
        • Jansonius N.M.
        Myopia as a risk factor for open-angle glaucoma: a systematic review and meta-analysis.
        Ophthalmology. 2011; 118: 1989-1994
        • Tano Y.
        Pathologic myopia: where are we now?.
        Am J Ophthalmol. 2002; 134: 645-660
        • Walline J.J.
        • Lindsley K.
        • Verdula S.S.
        • et al.
        Interventions to slow progression of myopia in children.
        Cochrane Database Syst Rev. 2011; : CD004916
        • McBrien N.A.
        • Moghaddam H.O.
        • Reeder A.P.
        Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism.
        Invest Ophthalmol Vis Sci. 1993; 34: 205-215
        • McBrien N.A.
        • Stell W.K.
        • Carr B.
        How does atropine exert its anti-myopia effects?.
        Ophthalmic Physiol Opt. 2013; 33: 373-378
        • McBrien N.A.
        • Jobling A.I.
        • Truong H.T.
        • et al.
        Expression of muscarinic receptor subtypes in tree shrew ocular tissues and their regulation during the development of myopia.
        Mol Vis. 2009; 15: 464-475
        • Prepas S.B.
        Light, literacy and the absence of ultraviolet radiation in the development of myopia.
        Med Hypotheses. 2008; 70: 635-637
        • Lin H.J.
        • Wei C.C.
        • Chang C.Y.
        • et al.
        Role of chronic inflammation in myopia progression: clinical evidence and experimental validation.
        EBioMedicine. 2016; 10: 269-281
        • Oxford Centre for Evidence-Based Medicine
        Levels of evidence.
        (Accessed November 4, 2017)
        • Yen M.Y.
        • Liu J.H.
        • Kao S.C.
        • Shiao C.H.
        Comparison of the effect of atropine and cyclopentolate on myopia.
        Ann Ophthalmol. 1989; 21 (187): 180-182
        • Shih Y.F.
        • Chen C.H.
        • Chou A.C.
        • et al.
        Effects of different concentrations of atropine on controlling myopia in myopic children.
        J Ocul Pharmacol Ther. 1999; 15: 85-90
        • Shih Y.F.
        • Hsiao C.K.
        • Chen C.J.
        • et al.
        An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression.
        Acta Ophthalmol Scand. 2001; 79: 233-236
        • Syniuta L.A.
        • Isenberg S.J.
        Atropine and bifocals can slow the progression of myopia in children.
        Binocul Vis Strabismus Q. 2001; 16: 203-208
        • Chua W.H.
        • Balakrishnan V.
        • Chan Y.H.
        • et al.
        Atropine for the treatment of childhood myopia.
        Ophthalmology. 2006; 113: 2285-2291
        • Tong L.
        • Huang X.L.
        • Koh A.L.
        • et al.
        Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine.
        Ophthalmology. 2009; 116: 572-579
        • Chia A.
        • Chua W.H.
        • Tan D.
        Effect of topical atropine on astigmatism.
        Br J Ophthalmol. 2009; 93: 799-802
        • Chia A.
        • Chua W.H.
        • Cheung Y.B.
        • et al.
        Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).
        Ophthalmology. 2012; 119: 347-354
        • Chia A.
        • Li W.
        • Tan D.
        • Luu C.D.
        Full-field electroretinogram findings in children in the atropine treatment for myopia (ATOM2) study.
        Doc Ophthalmol. 2013; 126: 177-186
        • Chia A.
        • Chua W.H.
        • Wen L.
        • et al.
        Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%.
        Am J Ophthalmol. 2014; 157: 451-457
        • Kumaran A.
        • Htoon H.M.
        • Tan D.
        • Chia A.
        Analysis of changes in refraction and biometry of atropine- and placebo-treated eyes.
        Invest Ophthalmol Vis Sci. 2015; 56: 5650-5655
        • Brodstein R.S.
        • Brodstein D.E.
        • Olson R.J.
        • et al.
        The treatment of myopia with atropine and bifocals. A long-term prospective study.
        Ophthalmology. 1984; 91: 1373-1379
        • Chiang M.F.
        • Kouzis A.
        • Pointer R.W.
        • Repka M.X.
        Treatment of childhood myopia with atropine eyedrops and bifocal spectacles.
        Binocul Vis Strabismus Q. 2001; 16: 209-215
        • Cooper J.
        • Eisenberg N.
        • Schulman E.
        • Wang F.M.
        Maximum atropine dose without clinical signs or symptoms.
        Optom Vis Sci. 2013; 90: 1467-1472
        • Polling J.R.
        • Kok R.G.
        • Tideman J.W.
        • et al.
        Effectiveness study of atropine for progressive myopia in Europeans.
        Eye (Lond). 2016; 30: 998-1004
        • Loughman J.
        • Flitcroft D.I.
        The acceptability and visual impact of 0.01% atropine in a Caucasian population.
        Br J Ophthalmol. 2016; 100: 1525-1529
        • Chia A.
        • Lu Q.S.
        • Tan D.
        Five-year clinical trial on Atropine for the Treatment of Myopia 2: myopia control with atropine 0.01% eyedrops.
        Ophthalmology. 2016; 123: 391-399
        • Luu C.D.
        • Lau A.M.
        • Koh A.H.
        • Tan D.
        Multifocal electroretinogram in children on atropine treatment for myopia.
        Br J Ophthalmol. 2005; 89: 151-153
        • Li S.M.
        • Wu S.S.
        • Kang M.T.
        • et al.
        Atropine slows myopia progression more in Asian than white children by meta-analysis.
        Optom Vis Sci. 2014; 91: 342-350